

REMARKS

Claim 19 is pending in the application. Claims 2, 16, 20-25, and 34 have been previously cancelled. Previously withdrawn claims 26-33 and 35 are cancelled without prejudice by this amendment, as are claims 1, 3-15, 17, and 18. Claim 19 has been amended to incorporate language suggested by the Examiner to address an objection to claim 19.

Applicants respectfully submit that: (1) no new matter has been added to the application by the amendment; (2) the amendment resolves all issues raised by the Examiner in the final Office Action of May 21, 2007; (3) the subject matter of the amendment already has been included in the Examiner's search and therefore does not require the Examiner to perform a new search; (4) the amendment places the application in condition for allowance or in better condition for appeal; and (5) the amendment does not result in a net addition of claims to the application. Applicants respectfully request that this Amendment After Final Rejection be entered in accordance with 37 C.F.R. §116 and M.P.E.P. 714.13.

Claim Objections

The Examiner has objected claims 1, 3-15, and 17-19, and particularly to the wording of claims 1 and 19. In view of the Examiner's comments, Applicants have amended claim 19 to recite "oligomeric ABA-glycidyl methacrylate diester" as suggested by the Examiner. Applicants respectfully submit that with these amendments, the objection raised by the Examiner regarding claim 19 has been addressed. Accordingly, Applicants respectfully request that the objection to claim 19 be withdrawn. In view of cancellation of claims 1, 3-15, 17, and 18, objection to these claims is now moot.

Claim Rejections – 35 U.S.C. § 102 – claims 1, 3, 6, 7, 14, 15, 17, and 18

The Examiner has rejected claims 1, 3, 6, 7, 14, 15, 17, and 18 under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 5,700,581 (Sachdev *et al.*, hereinafter "Sachdev '581"). In view of cancellation of these claims, this rejection is now moot.

Claim Rejections – 35 U.S.C. § 102/103 – claims 1, 3, 6, 7, 14, 15, 17, and 18

The Examiner has rejected claims 1, 3, 6, 7, 14, 15, 17, and 18 under 35 U.S.C. §102(b) as being anticipated by, or in the alternative, under 35 U.S.C. §103(a) as obvious over, U.S. Patent No. 6,548,175 (Sachdev *et al.*, hereinafter “Sachdev ‘175”). In view of cancellation of these claims, this rejection is now moot.

Claim Rejections – 35 U.S.C. § 103 – claims 4, 5, 8, 12, and 13

The Examiner has rejected claims 4, 5, 8, 12, and 13 under 35 U.S.C. §103(a) as unpatentable over Sachdev ‘581. In view of cancellation of these claims, this rejection is now moot.

Claim Rejections – 35 U.S.C. § 103 – claim 8

The Examiner has rejected claim 8 under 35 U.S.C. §103(a) as obvious over Sachdev ‘175. In view of cancellation of claim 8, this rejection is now moot.

Claim Rejections – 35 U.S.C. § 103 – claims 9-11

The Examiner has rejected claims 9-11 under 35 U.S.C. §103(a) as obvious over Sachdev ‘581 or Sachdev ‘175 in view of U.S. Patent No. 6,977,025 (McArdle *et al.*, hereinafter “McArdel”). In view of cancellation of these claims, this rejection is now moot.

Claim Rejections -- Double Patenting – claims 1, 14, and 15

The Examiner has rejected claims 1, 14, and 15 on the ground of nonstatutory obviousness-type double patenting as unpatentable over claims 1-22 of Sachdev ‘581. In view of cancellation of these claims, this rejection is now moot.

Claim Rejections – Double Patenting – claims 3-8, 12, 13, 17, and 18

The Examiner has rejected claims 3-8, 12, 13, 17, and 18 on the ground of nonstatutory obviousness-type double patenting as unpatentable over claims 1-22 of Sachdev ‘581, in light of the specification. In view of cancellation of these claims, this rejection is now moot.

Claim Rejections – Double Patenting – claims 1, 14, and 15

The Examiner has rejected claims 1, 14, and 15 on the ground of nonstatutory obviousness-type double patenting as unpatentable over claims 1-15 of Sachdev '175. In view of cancellation of these claims, this rejection is now moot.

Claim Rejections – Double Patenting – claims 3, 6-8, 17, and 18

The Examiner has rejected claims 3, 6-8, 17, and 18 on the ground of nonstatutory obviousness-type double patenting as unpatentable over claims 1-15 of Sachdev '175, in light of the specification. In view of cancellation of these claims, this rejection is now moot.

Claim Rejections -- Double Patenting -- claims 9-11

The Examiner has rejected claims 9-11 on the ground of nonstatutory obviousness-type double patenting as unpatentable over claims 1-22 of Sachdev '581, or over claims 1-15 of Sachdev '175, in light of the specifications, and in view of McArdle. In view of cancellation of these claims, this rejection is now moot.

Allowable Subject Matter



Applicants acknowledge that claim 19 has been found to recite allowable subject matter, and would be allowable if rewritten to overcome an objection to the claim. In view of the Examiner's comments, claim 19 has been amended as discussed above.

CONCLUSION

In view of the foregoing amendment and remarks, Applicants respectfully submit that the present application, including claim 19, is in condition for allowance, and such action is respectfully requested.

Respectfully submitted,

KRISHNA G. SACHDEV, ET AL.


July 25, 2007 By: 

(Date) **KERRY GOODWIN**
Registration No. 48,955
IBM CORPORATION
Dept. 18G
BLDG. 300-483
2070 Route 52
Hopewell Junction, NY 12533
Direct Dial: 845-892-9645
Facsimile: 845-892-6363
E-Mail: kerry.goodwin@us.ibm.com